Chongqing Precision Biotech Co., Ltd

This early-phase study tests a new type of CAR T-cell therapy for people with blood cancers like leukemia, lymphoma, or multiple myeloma that have returned or not improved with standard treatments. The therapy uses a patient's own immune cells, modified to target and attack cance…

This early-stage study tests a new treatment called CEA-targeted CAR-T cells for people with advanced solid tumors (such as lung, stomach, colon, rectal, esophageal, or pancreatic cancer) that have not responded to standard therapies. The treatment uses a patient's own immune cel…

This early-phase trial tests a new treatment called MC-1-50 for adults with severe lupus that hasn't improved with standard therapies. The treatment uses a patient's own immune cells, modified to target and destroy faulty immune cells driving the disease. The main goals are to ch…

This study is testing a new treatment using specially engineered immune cells (CAR-T cells) in children aged 5 and older with severe rheumatic diseases like juvenile dermatomyositis, arthritis, systemic sclerosis, and Sjögren's syndrome that haven't improved with standard therapi…

This early-stage study tests a personalized cell therapy (CAR-T) for people with severe lupus that hasn't improved with standard treatments. The therapy uses the patient's own immune cells, modified to target and calm the overactive immune system. The goal is to safely reduce dis…

This early-stage study tests a new type of CAR-T cell therapy for people with severe lupus that hasn't improved with standard treatments. The therapy uses a person's own immune cells, modified to target and calm the overactive immune system. The goal is to reduce disease activity…

This early-stage study tests a new treatment called PIC1 injection for adults with relapsed or refractory B-cell Non-Hodgkin lymphoma, a type of blood cancer that has not responded to standard therapies. The main goal is to check the safety of the injection and see how many patie…

This early-stage study tests a new treatment called CD70-targeted CAR-T cells in people with advanced solid tumors, including kidney, lung, and ovarian cancers. The therapy uses a patient's own immune cells, modified to recognize and attack cancer cells that have a specific marke…

This early-stage study tests a new, fast-made CAR-T cell therapy for people with severe lupus that hasn't improved with standard treatments. The therapy uses a person's own immune cells, modified to target and calm the overactive immune system causing lupus. The main goals are to…